Cargando…
Health Outcomes at School Age among Children Who Are HIV-Exposed but Uninfected with Detected Mitochondrial DNA Depletion at One Year
Infant antiretroviral (ARV) prophylaxis given to children who are human immunodeficiency virus (HIV)-exposed but uninfected (CHEU) to prevent HIV transmission through breastfeeding previously proved its efficacy in the fight against the pediatric epidemic. However, few studies have investigated the...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696966/ https://www.ncbi.nlm.nih.gov/pubmed/33207772 http://dx.doi.org/10.3390/jcm9113680 |
_version_ | 1783615525568380928 |
---|---|
author | Monnin, Audrey Nagot, Nicolas Eymard-Duvernay, Sabrina Meda, Nicolas Tumwine, James K. Tylleskär, Thorkild de Perre, Philippe Van Molès, Jean-Pierre |
author_facet | Monnin, Audrey Nagot, Nicolas Eymard-Duvernay, Sabrina Meda, Nicolas Tumwine, James K. Tylleskär, Thorkild de Perre, Philippe Van Molès, Jean-Pierre |
author_sort | Monnin, Audrey |
collection | PubMed |
description | Infant antiretroviral (ARV) prophylaxis given to children who are human immunodeficiency virus (HIV)-exposed but uninfected (CHEU) to prevent HIV transmission through breastfeeding previously proved its efficacy in the fight against the pediatric epidemic. However, few studies have investigated the short- and long-term safety of prophylactic regimens. We previously reported a decrease of mitochondrial DNA (mtDNA) content among CHEU who received one year of lamivudine (3TC) or lopinavir-boosted ritonavir (LPV/r) as infant prophylaxis. We aimed to describe mtDNA content at six years of age among these CHEU, including those for whom we identified mtDNA depletion at week 50 (decrease superior or equal to 50% from baseline), and to compare the two prophylactic drugs. We also addressed the association between mtDNA depletion at week 50 with growth, clinical, and neuropsychological outcomes at year 6. Quantitative PCR was used to measure mtDNA content in whole blood of CHEU seven days after birth, at week 50, and at year 6. Among CHEU with identified mtDNA depletion at week 50 (n = 17), only one had a persistent mtDNA content decrease at year 6. No difference between prophylactic drugs was observed. mtDNA depletion was not associated with growth, clinical, or neuropsychological outcomes at year 6. This study brought reassuring data concerning the safety of infant 3TC or LPV/r prophylaxis. |
format | Online Article Text |
id | pubmed-7696966 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76969662020-11-29 Health Outcomes at School Age among Children Who Are HIV-Exposed but Uninfected with Detected Mitochondrial DNA Depletion at One Year Monnin, Audrey Nagot, Nicolas Eymard-Duvernay, Sabrina Meda, Nicolas Tumwine, James K. Tylleskär, Thorkild de Perre, Philippe Van Molès, Jean-Pierre J Clin Med Article Infant antiretroviral (ARV) prophylaxis given to children who are human immunodeficiency virus (HIV)-exposed but uninfected (CHEU) to prevent HIV transmission through breastfeeding previously proved its efficacy in the fight against the pediatric epidemic. However, few studies have investigated the short- and long-term safety of prophylactic regimens. We previously reported a decrease of mitochondrial DNA (mtDNA) content among CHEU who received one year of lamivudine (3TC) or lopinavir-boosted ritonavir (LPV/r) as infant prophylaxis. We aimed to describe mtDNA content at six years of age among these CHEU, including those for whom we identified mtDNA depletion at week 50 (decrease superior or equal to 50% from baseline), and to compare the two prophylactic drugs. We also addressed the association between mtDNA depletion at week 50 with growth, clinical, and neuropsychological outcomes at year 6. Quantitative PCR was used to measure mtDNA content in whole blood of CHEU seven days after birth, at week 50, and at year 6. Among CHEU with identified mtDNA depletion at week 50 (n = 17), only one had a persistent mtDNA content decrease at year 6. No difference between prophylactic drugs was observed. mtDNA depletion was not associated with growth, clinical, or neuropsychological outcomes at year 6. This study brought reassuring data concerning the safety of infant 3TC or LPV/r prophylaxis. MDPI 2020-11-16 /pmc/articles/PMC7696966/ /pubmed/33207772 http://dx.doi.org/10.3390/jcm9113680 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Monnin, Audrey Nagot, Nicolas Eymard-Duvernay, Sabrina Meda, Nicolas Tumwine, James K. Tylleskär, Thorkild de Perre, Philippe Van Molès, Jean-Pierre Health Outcomes at School Age among Children Who Are HIV-Exposed but Uninfected with Detected Mitochondrial DNA Depletion at One Year |
title | Health Outcomes at School Age among Children Who Are HIV-Exposed but Uninfected with Detected Mitochondrial DNA Depletion at One Year |
title_full | Health Outcomes at School Age among Children Who Are HIV-Exposed but Uninfected with Detected Mitochondrial DNA Depletion at One Year |
title_fullStr | Health Outcomes at School Age among Children Who Are HIV-Exposed but Uninfected with Detected Mitochondrial DNA Depletion at One Year |
title_full_unstemmed | Health Outcomes at School Age among Children Who Are HIV-Exposed but Uninfected with Detected Mitochondrial DNA Depletion at One Year |
title_short | Health Outcomes at School Age among Children Who Are HIV-Exposed but Uninfected with Detected Mitochondrial DNA Depletion at One Year |
title_sort | health outcomes at school age among children who are hiv-exposed but uninfected with detected mitochondrial dna depletion at one year |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696966/ https://www.ncbi.nlm.nih.gov/pubmed/33207772 http://dx.doi.org/10.3390/jcm9113680 |
work_keys_str_mv | AT monninaudrey healthoutcomesatschoolageamongchildrenwhoarehivexposedbutuninfectedwithdetectedmitochondrialdnadepletionatoneyear AT nagotnicolas healthoutcomesatschoolageamongchildrenwhoarehivexposedbutuninfectedwithdetectedmitochondrialdnadepletionatoneyear AT eymardduvernaysabrina healthoutcomesatschoolageamongchildrenwhoarehivexposedbutuninfectedwithdetectedmitochondrialdnadepletionatoneyear AT medanicolas healthoutcomesatschoolageamongchildrenwhoarehivexposedbutuninfectedwithdetectedmitochondrialdnadepletionatoneyear AT tumwinejamesk healthoutcomesatschoolageamongchildrenwhoarehivexposedbutuninfectedwithdetectedmitochondrialdnadepletionatoneyear AT tylleskarthorkild healthoutcomesatschoolageamongchildrenwhoarehivexposedbutuninfectedwithdetectedmitochondrialdnadepletionatoneyear AT deperrephilippevan healthoutcomesatschoolageamongchildrenwhoarehivexposedbutuninfectedwithdetectedmitochondrialdnadepletionatoneyear AT molesjeanpierre healthoutcomesatschoolageamongchildrenwhoarehivexposedbutuninfectedwithdetectedmitochondrialdnadepletionatoneyear |